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Background. Patients with SCD now usually live well into adulthood. Whereas transitions into adulthood are now often studied, little
is published about aging beyond the transition period. We therefore studied age-associated SCD differences in utilization, pain, and
psychosocial variables. Methods. Subjects were 232 adults in the Pain in Sickle Cell Epidemiology Study (PiSCES). Data included
demographics, comorbidity, and psychosocial measures. SCD-related pain and health care utilization were recorded in diaries. We
compared 3 age groups: 16–25 (transition), 26–36 (younger adults), and 37–64 (older adults) years. Results. Compared to the 2 adult
groups, the transition group reported fewer physical challenges via comorbidities, somatic complaints, and pain frequency, though
pain intensity did not differ on crisis or noncrisis pain days. The transition group utilized opioids less often, made fewer ambulatory
visits, and had better quality of life, but these differences disappeared after adjusting for pain and comorbidities. However, the
transition group reported more use of behavioral coping strategies. Conclusion. We found fewer biological challenges, visits, and
better quality of life, in transition-aged versus older adults with SCD, but more behavioral coping. Further study is required to
determine whether age-appropriate health care, behavioral, or other interventions could improve age-specific life challenges of
patients with SCD.

1. Introduction
Sickle cell disease (SCD) is an autosomal recessive genetic
disorder of hemoglobin structure whose classic symptomatic
manifestations are acute episodes of ischemic pain, termed
vasoocclusive crises (VOC), from deformed red blood cells.
VOC may begin within the first year of life and generally
continue throughout life. VOC worsen with age [1–3] even
among children [4, 5]. VOC may often require costly emergency care, hospitalization, and/or opioids for relief [6, 7].
Fortunately, newborn screening [8], prophylactic penicillin [9], screening for stroke, and prevention of stroke

with red cell transfusions [10] and hydroxyurea [11–14] have
put a huge dent in the previously high SCD morbidity and
mortality rate in childhood [15], from deadly infections and
strokes and in adulthood from vasoocclusive complications
and organ failure. While in 1970 the estimated median
survival for people with SCD was just 20 years [16], today
many with SCD are living well into adulthood. Perhaps the
first generation to have many survivors past age 40, the
majority of living SCD patients are now adults, with a median
age at death over 40 [17, 18]. Still, adults with SCD face unique
challenges related to mounting comorbidities of organ failure
as well as the general challenges of aging [19–23]. There are

2
well-documented age-related changes in hospital utilization
throughout the lifecycle [6].
Not surprisingly, the adolescent transition period to
adulthood has become an intense focus of health services and
implementation research in SCD, because it is fraught with
difficulty. Many have described the challenges of transition to
adulthood from pediatric care [24–28]. Like all adolescents
and young adults, SCD patients must learn to manage the
uncertainties of transitioning out of their homes of origin,
obtaining training and education, and seeking employment
if they are healthy enough. But in addition, SCD transitionage patients must learn to manage their chronic disease,
negotiate care on their own with providers, and cope with
an often stark, more disjointed adult health care system,
compared to the pediatric system. Further, hospitals face
ballooning utilization of emergency and hospital services by
SCD patients during the adolescent transition period [29–
31]. Behavioral and other interventions are being tested to
improve the transition from pediatric to adult SCD care, such
as peer mentoring, teaching self-care, or improving patient
activation [32–37].
However, in contrast, few have studied age-specific life
challenges, including biological challenges and psychosocial
challenges, beyond the transition period, that is, among the
oldest SCD patients. Most previous studies of utilization and
their predictors among adult SCD patients were done with
adults with an average age of 30 years [38]. It is conceivable
that if age-specific challenges were found in these older SCD
adults, specific interventions could be crafted to improve the
quantity and quality of their lives, similar to what are being
developed for transition-aged patients.
We are therefore interested in several age-associated
differences among adults with SCD. We theorized three age
groups by stage of life: transition-aged, younger adults, and
older adults. Building off of ours [39] and others’ earlier
theories we hypothesized that older SCD patients, due to
aging and organ failure, would report more comorbidities,
have worse laboratory measures, and report worse functional
status and more health care utilization than the younger
adults or transition-aged groups. On the other hand, we
hypothesized that those in the transition-aged group would,
due to more disruption in social support and living conditions, utilize services more than slightly older, presumably
better-adjusted, but still “young” adults, who might be enjoying their “stable, family” years. Finally, due to more comorbid
illness in the older adult groups, we hypothesized that each
of these groups might report more pain, more psychosocial
dysfunction, and poorer coping than the younger adult group.

2. Methods
PiSCES (the Pain in Sickle Cell Epidemiology Study) was a
longitudinal study of pain in SCD but also a methodologic
study of the relationship among measures of pain, crises,
and utilization in sickle cell disease. The methods of PiSCES
have been described in detail elsewhere [40, 41]. Briefly, we
enrolled patients from July 2002 to August 2004. We collected
baseline information including demographic characteristics
and medical history, physical and mental health related
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quality of life (HRQOL), depression, alcoholism, somatic
symptom burden, sickle cell-related stress, coping styles, and
social support. We collected laboratory data via blood and
urine samples. Patients then kept daily pain diaries for up to 6
months, including names and amounts of opioid-containing
medications taken.
We recruited patients 16 years of age or older from across
Virginia, mostly from the Richmond (central Virginia) and
Tidewater (coastal) areas. Both the study and our recruitment
methods were approved by the Institutional Review Board
of Virginia Commonwealth University, Richmond, Virginia,
and we obtained informed consent.
Patients received routine care for their sickle cell disease from either community-based physicians or sickle cell
specialist physicians associated with academic medical centers (two physicians at Virginia Commonwealth University
Health System serving the Richmond area and one physician
associated with Eastern Virginia Medical School, Norfolk,
Virginia, serving the Tidewater region). Emergent care for the
cohort was provided in Emergency Departments regardless
of the patients’ usual source of ambulatory care. No day
hospitals for sickle cell disease are located in the region.
2.1. Measures. Coping was assessed using the Coping Strategy Questionnaire-SCD (CSQ-SCD), originally developed to
measure cognitive and behavioral coping styles in chronic
ow back pain [42]. This scale was later revised for patients
with SCD with the addition of items related to strategies particularly relevant to SCD [38]. The adapted Coping Strategy
Questionnaire-SCD includes 78 items (each rated on Likert
scale from 0 to 6). While there are 13 subscales of 6 items
each, we followed the methods and results of Anie et al. [43]
(also confirmed by our own factor analysis) and used the 3
scales: active coping (ignoring pain sensations, reinterpreting
pain sensations, calming self-statements, diverting attention,
and increasing behavioral activities), affective or emotional
coping (anger, fear, catastrophizing, praying and hoping,
and isolation), and passive or behavioral adherence coping
(taking fluids, resting, and heat/cold/massage). Scores are
means of the subscales.
The Smith-Bovbjerg Sickle Cell Stress scale (STRESS)
is a 10-item scale that assesses stress using our internally
developed measure (Cronbach’s alpha 0.84). More specifically, items are measured on a Likert scale from 0 (strongly
disagree) to 4 (strongly agree) and assess issues as worry
about access to pain medication or whether pain medication
will control pain, being hospitalized, limited work activities,
sexual performance, insurance, and so on. Higher scores
indicate more perceived stress.
Health related quality of life was assessed at baseline using
the Medical Outcome Study 36-item short form (MOS SF36), one of the earliest well-known and accepted generic
measures of HRQOL [44]. There are eight SF-36 subscales
measured on a scale from 0 to 100 (worst to best) as well as
two summary scales of physical and mental health. The SF-36
has good reliability and validity in subjects with chronic pain
[45, 46]. We have reported overall SF-36 results of PiSCES
elsewhere [47].
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Social Support was measured using the Multidimensional
Scale of Perceived Social Support [48, 49]. Patients rated 12
items on a scale from 1 to 7 regarding the amount of support
received from family, friends, and significant others. Higher
mean values indicate better perceived social support.
Depression, anxiety, alcohol abuse, and somatic symptoms were each measured using the Patient Health Questionnaire (PHQ). The PHQ is a widely utilized screening
instrument based on subjects’ self-reported symptoms that
was designed to facilitate the recognition and diagnosis of
the most common mental disorders in primary care subjects
[50]. For the purposes of this study, we combined the two
depression diagnoses generated by the PHQ (Major Depressive Syndrome, Other Depressive Syndrome) and combined
the two anxiety diagnoses (Panic Syndrome, Other Anxiety
Syndrome) into a single category of depression/anxiety [51].
The designation of alcohol abuse was also derived from the
PHQ [52].
Somatic symptom burden was assessed with the portion
of the PHQ referred to as the PHQ-15 [53], which includes 15
physical symptoms (like headaches, dizziness, heart pounding, sleep problems, nausea, bowel function issues, etc.) that
account for more than 90% of symptoms seen in primary care
(exclusive of upper respiratory symptoms such as cough).
Patients with higher somatic symptom scores have been
found to use more health care (both inpatient and outpatient)
and this relationship remains strong after controlling for
presence of comorbid psychiatric conditions. In order to
avoid measuring overlapping physical symptoms which could
be accounted for by SCD instead of somatization, we excluded
four common pain sites of SCD (limb, back, stomach, and
chest) and used an 11-item version referred to as PHQscd [54].
Daily pain assessment utilized daily diaries completed
by patients for up to 6 months. Patients were encouraged
at the initial baseline visit and with reminder calls by study
staff to return diaries daily by mail using provided stamped
envelopes. They received payment for each returned diary,
with a higher payment in the latter 2 months of the study to
encourage study completion. We modeled the diary after that
of the Multicenter Study of Hydroxyurea (MSH) [55]. Patients
reported about the prior 24 hours. They rated their worst
sickle cell pain intensity (0–9) and marked a body diagram
to indicate where they hurt [56]. In addition, they reported
whether they were in a “crisis” and whether they had made a
visit to the emergency department (ED) and hospital or either
a scheduled or unscheduled clinic visit because of sickle cell
pain. Patients also indicated what medication they had taken.
Crisis days were self-defined by each patient using a check
box on each daily diary.
2.2. Statistical Analysis. For purposes of analysis, we defined
home days as days without ED or hospital utilization marked
on the diary and pain days as days when pain intensity was
rated 1 or higher on the 0–9 scale. We defined opioid use as the
report of use of any of the known opioids then on the market,
inclusive of Tramadol.
Mean scores of pain intensity as well as rates of pain
occurrence, health care utilization, and home opioid use were
calculated for each patient using daily diary information.
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Since the number of diaries completed by each subject varied,
the numbers of pain days, opioid use days, crisis days, and
utilization days were converted to percentages by dividing by
the total number of diary days completed by each subject.
The exception was the percentage of home pain days on
opiates, which used home pain days as the denominator. The
denominator for mean pain was pain days. For mean pain on
crisis days we used number of diary days reporting crisis in
the denominator, while for mean pain on noncrisis days the
denominator was number of pain days without crisis.
A measure called ED reliance (referred to here as ED
reliance–health care) was calculated as the proportion of
ambulatory visits (ED + outpatient visits) that are ED visits
[57]. This measure is said to be able to distinguish between
ED visits due to lack of adequate access to primary care versus
increased need. A value greater than .33 is considered high.
An additional ED reliance related measure (referred to as ED
reliance–crisis) was created as the proportion of total number
of crises that were treated at the ED/hospital as opposed to at
home.
Guided by our cited hypotheses, as well as by Sanders et
al. [58], who compared 70 adults 18–36 versus a group aged 37
and above, we divided patients into 3 age groups: transition
(ages 16–25), younger adults (ages 26–36), and older (ages
37 and above) adult groups. Categorical measures were
compared using a Chi-square test; Bonferroni correction was
used when pairwise comparisons were made. Continuous
measures were compared across these 3 age categories using
analysis of variance. In certain cases we controlled for percent
pain days and number of SCD comorbidities. Tukey’s method
was used to compare age categories pairwise while controlling
for multiple comparisons in ANOVA and ANCOVA.
Analyses were conducted by using SAS, version 9.4 for
Windows (SAS Institute, Cary, North Carolina).
2.3. Role of the Funding Source. The National Heart, Lung,
and Blood Institute provided an unrestricted grant for this
project. The funding source did not have any influence on the
planning, conduct, analysis, or publication of this study or its
results.

3. Results
Table 1 shows that a total of 57 subjects were in the transition
group, (ages 16–25), 71 subjects were in the younger adult
group (ages 26–36), and 104 subjects were in our older adult
group (ages 37–64). Compared to the two adult groups, the
transition group was less likely to have gone to college or be
married, likely a direct effect of their age/stage in life. The two
adult groups had similar education levels. Income and genotype were similar across age groups. A similar proportion of
subjects among each age group attended specialty medical
care centers for SCD.
Subjects in both the transition group and the younger
adult group recalled significantly fewer comorbidities and less
often reported ischemic ulcers, hypertension, or rheumatic
diseases over their lifetime compared to the older group.
Subjects in the transition group also less often recalled
avascular necrosis and gout than did those in the adult
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Table 1: Demographic, biological variables, depression, anxiety, and alcohol abuse1 .

Variable
Gender
Male
Female
Education
<High school
High school
>High school
Marital status
Married
Unmarried
Income
≤10,000
10,000–20,000
20,001–30,000
>30,000
Genotype
S𝛽0 Thal
S𝛽+ Thal
SC
SS
Seen at SCD specialty center
Y
N
Number of comorbidities
Depression/anxiety
Y
N
Alcohol abuse
Y
N
Lab values2
%F
HbA
HbC
HbS
HCT
WBC

Transition group (ages 16–25)
𝑁 = 57

Younger adults (ages 26–36)
𝑁 = 71

Older adults (ages 37–64)
𝑁 = 104

23 (40.3)
34 (59.7)

27 (38.0)
44 (62.0)

39 (37.5)
65 (61.0)

𝑝 value
0.936

0.008ab
13 (22.8)
26 (45.6)
18 (31.6)

5 (7.0)
26 (36.6)
40 (56.3)

10 ( 9.6)
36 (34.6)
58 (55.8)
<0.001abc

1 (1.7)
56 (98.3)

12 (16.9)
59 (83.1)

42 (40.4)
62 (59.6)

22 (41.5)
11 (20.7)
6 (11.3)
14 (26.4)

27 (38.0)
17 (23.9)
12 (16.9)
15 (21.1)

39 (37.9)
24 (23.3)
16 (15.5)
24 (23.3)

0.972

0.793
1 (1.7)
1 (1.7)
10 (17.5)
45 (78.9)

1 (1.4)
2 (2.9)
17 (24.3)
50 (71.4)

3 ( 2.9)
3 ( 2.9)
29 (27.9)
69 (66.3)

27 (49.1)
39 (50.9)
1.9 (0.2)

35 (51.5)
36 (48.5)
2.1 (0.2)

48 (46.1)
56 (53.9)
3.0 (0.2)

8 (14.0)
49 (86.0)

26 (36.6)
45 (63.4)

33 (31.7)
71 (68.3)

14 (24.6)
43 (75.4)

22 (31.0)
49 (69)

36 (34.6)
68 (65.4)

5.1 (1.1)
7.7 (2.9)
8.8 (2.9)
78.3 (2.9)
26.3 (0.8)
11.4 (0.7)

2.9 (1.0)
13.2 (2.6)
10.9 (2.6)
71.6 (2.1)
28.2 (0.7)
11/0 (0.6)

3.9 (0.8)
13.3 (2.2)
13.0 (2.1)
65.8 (2.2)
27.1 (0.6)
10.7 (0.5)

0.788

<0.001bc
0.014ab

0.419

0.319
0.262
0.485
0.003b
0.238
0.726

1

Frequency (%) or mean (SD).
Reduced sample size for labs (푛 = 193, 201, 200, 212, 203, and 169 for % F, HbA, HbC, HbS, HbS, HCT, and WBC).
Multiple comparisons (Bonferroni, Tukey): significant differences in unadjusted analyses, transition versus younger adults a ; transition versus older adults b ;
younger versus older adults c .
2

groups (specific comorbidities are reported in Supplemental Table 1 in Supplementary Material available online at
https://doi.org/10.1155/2017/4070547). Subjects in the transition group were less likely to be depressed/anxious than either
of the adult groups, but this difference did not persist when
controlling for frequency of pain and comorbidities.

Table 2 shows that the subjects in either the younger or
older adults had nearly twice the percentage of pain days, had
twice the average pain intensity among all days, and hurt at
nearly one-and-a-half times as many body sites as those in
transition group. However, subjects did not differ with regard
to the percent of days spent in crisis (though there was a
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Table 2: Pain-related variables (unadjusted means and standard errors).
Variable

Transition group (ages 16–25)
𝑁 = 57

Younger adults (ages 26–36)
𝑁 = 71

Older adults (ages 37–64)
𝑁 = 104

𝑝 value for overall
ANOVA

32.7 (4.8)
8.4 (3.0)

62.4 (4.3)
18.3 (2.7)

64.7 (3.6)
17.0 (2.3)

<0.001ab
0.033a

4.2 (0.2)
5.6 (0.3)
3.8 (0.2)

4.3 (0.2)
5.4 (0.2)
3.9 (0.2)

4.4 (0.2)
5.5 (0.2)
4.1 (0.2)

0.687
0.867
0.451

2.4 (0.3)

3.2 (0.2)

3.6 (0.2)

0.001b

% Pain days
% Crisis days
Mean pain intensity∗
Pain days
Crisis days
Noncrisis pain days
Mean # body parts that
hurt

Multiple comparisons (Bonferroni, Tukey): significant differences in unadjusted analyses, transition versus younger adults a ; transition versus older adults b ;
younger versus older adults c .
∗
Mean pain intensity, measured on days when pain was reported, varies from 1 to 9, with higher values implying more pain.

Table 3: Health care utilization (unadjusted means and standard errors).
Variables
% Home pain days on
opioids∗
% Days with ED visits
% Days in hospital
% Days with outpatient visit
% Days with any utilization
ED reliance-health care∗∗†
ED reliance-crisis†

Transition group (ages 16–25)
𝑁 = 57

Younger adults (ages 26–36)
𝑁 = 71

Older adults (ages 37–64)
𝑁 = 104

𝑝 value for
overall ANOVA

50.1 (5.3)

62.1 (4.5)

70.9 (3.8)

0.007b

1.1 (0.4)
1.9 (0.8)
1.5 (0.6)
3.7 (1.2)
36.7 (4.8)
19.8 (4.0)

2.2 (0.4)
3.0 (0.7)
2.7 (0.6)
6.9 (1.1)
39.6 (4.2)
14.2 (3.3)

1.1 (0.3)
1.8 (0.6)
3.6 (0.5)
5.9 (0.9)
19.3 (3.4)
10.6 (2.8)

0.079
0.365
0.029b
0.148
<0.001bc
0.171

Multiple comparisons (Tukey): significant differences in unadjusted analyses, transition versus younger adults a ; transition versus older adults b ; younger versus
older adults c .
∗
6 pts in the Transition Group, 1 in the younger adults, and 6 in the older adult groups did not have any home pain days, so are missing home days on opioids
∗∗
14 pts in the Transition Group, 18 in the younger adult, and 23 in the older adult group did not have either outpatient or ED visits reported on their diary, so
ED reliance could not be computed.
† represents percentage of ambulatory visits cared for in ED rather than outpatient or percentage of crises cared for at the hospital rather than at home. Higher
values imply more reliance on the ED/hospital.

numeric trend), or with regard to mean pain intensity on
crisis days or noncrisis pain days.
Regarding health care and opioid utilization, Table 3
shows that, before controlling for pain days and comorbidities, the transition group had fewer outpatient visits and used
opioids on fewer days than did the older adult group. When
controlling for pain days and comorbidities, differences in
outpatient visits among age groups were no longer significant
(2.7% versus 2.7% versus 2.9%, 𝑝 = 0.9179). There were no
significant differences for ED visits, hospital days, or total
health care utilization. Notably, ED reliance for health care
was twice as high for either the transition group or younger
adult group (which had similar values) as compared to the
older adult group. With values greater than 33 percent, the
two younger age groups had EDR which would be considered
excessive [29]. The ED reliance for crisis was not significantly
different when comparing the unadjusted averages, but,
after adjusting for comorbidities and percent pain days, the
transition group used the ED/hospital for a crisis rather than
self-care at home significantly more often than the two adult
groups (23.3 versus 13.8 versus 9.1, 𝑝 = 0.0237). There was also

a trend for the younger adult group to use the ED/hospital for
a crisis more than the older adult group.
Table 4 shows comparisons among age groups for
psychosocial variables and HRQOL. The transition group
reported significantly fewer somatic symptoms than the
younger or older adult groups, although these differences
were no longer significant when controlling for pain days and
comorbidities (6.2 versus 7.2 versus 7.5, 𝑝 = 0.1123). The
transition group also reported using significantly less passiveadherence coping than the younger adults. This difference
persisted when controlling for pain days and comorbidities.
The transition group reported significantly better physical
health (SF-36 physical summary score), which persisted
when controlling for pain days and comorbidities. All individual SF-36 subscales were significantly better for the transition group than for the two older groups, except for mental
functioning, where there were no significant differences
across age groups. When controlled for pain frequency and
comorbidities, vitality, physical functioning, and physical
role function subscales were still significantly better for the
transition group (individual subscales in Supplemental Table
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Table 4: Psychosocial variables, HRQOL∗ (unadjusted means and standard errors).

Somatic symptom score
Coping† (CSQ-SCD)
Active
Affective/emotional focused
Passive/behavioral adherence
HRQOL††
PCS
MCS
Social support
Stress

Transition group
(ages 16–25)
𝑁 = 57

Younger adults (ages
26–36)
𝑁 = 71

Older adults (ages
37–64)
𝑁 = 104

𝑝 value for overall
ANOVA∗∗

5.4 (0.5)

7.3 (0.4)

7.9 (0.4)

<0.002ab

2.6 (0.1)
2.1 (0.2)
3.6 (0.1)

2.9 (0.1)
2.6 (0.1)
4.2 (0.1)

3.0 (0.1)
2.5 (0.1)
4.0 (0.1)

0.078
0.058
0.008a

40.8 (1.3)
49.7 (1.5)
5.5 (0.2)
18.3 (1.34)

34.0 (1.1)
45.5 (1.5)
5.5 (0.2)
21.1 (1.2)

33.0 (0.9)
47.1 (1.1)
5.9 (0.1)
19.4 (1.0)

<0.001ab
0.102
0.112
0.263

∗

Higher scores are better, except for the stress measure.
Multiple comparisons (Tukey): significant differences in unadjusted analyses, transition versus younger adults a ; transition versus older adults b ; younger
versus older adults c .
†
Coping is measured using the Coping Strategies Questionnaire-SCD (CSQ-SCD).
††
HRQOL = Health Related Quality of Life, Measured using MOS SF-36: PCS = physical summary score. MCS = mental summary score.
∗∗

2). There were no differences between age groups in reports
of social support or SCD stress.

4. Discussion
Although our results are not the first to compare age groups
of patients with SCD with regard to disease or psychosocial
outcomes, our results are some of the first to compare simultaneously age differences in measures of physical outcomes,
utilization, pain outcomes, and psychosocial outcomes of
SCD adults. Our goal was to further test hypotheses about
important theoretical subthemes and potential predictors of
utilization of care and pain in SCD that we raised in 1997 [40].
For this study, we hypothesized age-related changes
in these predictors and outcomes. Regarding outcomes,
we hypothesized that pain, utilization (health care and
opioid), and psychosocial outcomes of older SCD adults
were sometimes even worse than those for transition-aged
adults. Regarding predictors, we hypothesized worse organ
failure (worse laboratory measures) and comorbidities for
older adults. We were aware that transition-aged adults
were already well-documented as having worse utilization of
health care, life disruption [6, 30], and HRQOL [59] than
pediatric patients. We therefore hypothesized that disruption
in social support and living conditions would be worse for
transition patients than for older adults and that this would
lead to transition patients utilizing services more than older,
presumably better-adjusted adults, who might be enjoying
their “stable, family” years. Our analyses confirmed some but
not all of our hypotheses. We found some age-related differences in all of the domains we measured: biomedical, utilization, pain, functional, and psychosocial. But often, the agerelated differences were not in the direction we hypothesized.
Regarding physical outcomes, consistent with our
hypotheses, the transition group did report fewer physical
challenges via comorbidities and non-SCD somatic

complaints. But contrary to our hypotheses, we found
few differences in hemoglobin or white cell count, other than
higher HbS. This is somewhat different than McKerrell et
al. [60] who, comparing patients under 30 to patients over
40, found significantly less evidence of organ damage in
younger patients: higher hemoglobin and platelet counts,
higher creatinine clearances, and lower BUN levels.
Also contrary to our hypotheses, the transition group
reported less frequent pain, pain in fewer locations, and
utilized opioids less often when in pain than either adult
groups. Interestingly, pain intensity did not differ significantly
between age groups on either crisis or noncrisis pain days.
This agreed with the results of Ahmed et al. [59].
Considering utilization, consistent with our disruption
hypotheses, the transition group made fewer ambulatory
visits unadjusted for pain days and number of comorbidities.
In addition, after adjustment, those in the transition group
were more likely to use ED/hospital resources to manage a
crisis than the older groups. An additional explanation for
this finding involves access to insurance. Minors with SCD
are likely to be on Medicaid [31] but lose eligibility when
they become adults. In Virginia, this occurs at the age of
18. To qualify for Medicaid as adults, one must meet severe
income limits and either be pregnant or be a parent or relative
caretaker of dependent children.
When considering psychosocial and behavioral outcomes, despite more unplanned visits, the transition group
reported less depression/anxiety, less behavioral coping, and
better HRQOL than older patients. This was consistent with
our hypotheses. In the case of behavioral coping strategies,
the differences were strong and remained after adjustment.
We have previously reported that catastrophizing did not
differ by age [61].
We also tested our hypotheses comparing younger (but
posttransition age) adults to older adults. Contrary to our
hypotheses, younger adults did not have less pain or better
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psychosocial function that older adults. Surprisingly, there
appeared to be a (nonsignificant) tendency for younger adults
to have more ED visits and hospitalizations than either the
transition group or older adults, who looked similar to each
other. Further, contrary to our hypotheses, based on other
differences in HRQOL, such as gender differences in PiSCES
[62] and childhood versus adult HRQOL in other studies
[23, 63, 64], we did not find that older adults reported
poorer functional status and utilized services more often than
younger adults. Older adults had higher comorbidity, but
fewer ED and hospital visits, suggesting that older adults
group were not faring worse than the younger adults after all.
Our findings can also be compared to those of Sanders et
al. [58] who studied age differences in adults but only studied
a single younger age group: 18–36, versus patients aged 37 and
older. Similar to their findings, we found no differences in
pain intensity during crisis or noncrisis days. Unlike Sanders
et al., though, we found no significant differences in ED visits
and hospitalizations. In fact, numerically it appeared that the
youngest people with SCD had similar number of ED visits
as the oldest adult group. Results from the CSQ-SCD also
differed, as we did not find the same differences (ignoring
pain, use of heat, and praying), while finding other differences
instead (calm, isolation, drinking, and resting). Subdividing
their younger group into a transition group and a young adult
group as we did appeared to reveal interesting differences
in findings for the transition group, who are still developing
both physically, emotionally, and socially, as well as for those
who were “old” for a SCD patient. The demographics of their
sample were similar in terms of marital status and education,
although they had slightly more females (68% versus our
60%) and slightly more patients with SS (81% versus our 71%),
generally considered the more severe genotype. It is possible
that their higher percentage of SS patients accounted for some
differences between results, but the differences in percentage
were small.
Ahmed et al. used similar age categories when comparing
SF-36 quality of life measures for a sample of people with
sickle cell disease in Saudi Arabia [59]. Contrary to our
findings, they did not find differences in physical function
across any age category, but they did find differences in mental health, with the younger group reporting better mental
health. Most quality of life measures differentiated functioning in children (up to age 17) as compared to adults of any age.
There appeared to be a trend for improvement with emotional
role limitations with age, which is the reverse of our sample
where those aged 16–25 had better emotional role functioning
[59]. Differences in results could be cultural, as Ahmed et al.
enrolled people from Saudi Arabia. Additionally, their sample
also had more males (58.8% versus 38% in our sample). We
previously found that QOL differed by gender, with males
having higher (more favorable) results [47]. Ahmed et al. also
found that family support was poorer for older adults, while
we found no differences in age groups. Family support could
potentially relate to reported mental health.
Blinder et al. [31] found that ED reliance increased until
age 22 and then remained high but relatively stable. In contrast, in PiSCES, the ED reliance was very similar for patients
in the 16–25 and 26–36 year age groups and then decreased by
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50% for patients over age 36. This did not change when controlling for pain and comorbidity. A similar pattern to PiSCES
was found in Hemker et al. [29], that is, the number of ED visits and the ED ratio were similar in transition-aged and young
adults but then decreased in adults 31–45 years old. The ED
reliance for health care is supposed to be able to distinguish
between increased need versus lack of adequate access to
primary care. The decrease in ED visits for older adults could
also be due to choice. These older adults were more likely
to treat their crises at home, which is consistent with lower
EDR for health care. One possible reason for this would be the
avoidance of the ED due to stigma developed with repeated
ED visits over the years which might negatively impact their
desire to utilize the ED [65]. It should be noted that both Blinder et al. [31] and Hemker et al. [29] followed SCD patients
with Medicaid in selected states, which means that their
results apply only to patients with some insurance coverage.
We did not find differences between age groups on
specialty care, with about 50% in specialty care across all age
groups. Thus even our youngest group, while transitioning
to adult care, still received specialty care at the same rate
as the others. This may have mitigated some of the findings
that others found for utilization, where specialty care may not
have been as common.
Ours was not a longitudinal study. As such, age differences we found could be due to cohort effects, rather than
specific age effects. Survival of only the “fittest” SCD patients
to an older age could explain some of the characteristics of
the older patient group. Also, pain and utilization summary
estimates were based on as few as 30 days and as many
as 188 days of diaries. Since pain may be episodic in SCD,
some important pain episodes could have been missed by
our diary methods. If this differed by age group it would bias
comparisons. We have no reason to believe, though, that this
missing data would differ by age. In fact, the distribution
of number of diary days was similar in the 3 age groups
(transition: 139 days; younger adults: 125 days; older adults:
138 days). Further, our study did not include children, so we
could make no comparisons of children versus adults, which
would have been useful to further explore our adolescent
disruption hypothesis

5. Conclusion
Many of our hypothesized age-associated differences in biological, psychosocial, quality of life, and utilization outcomes
in adults with SCD were confirmed. In general, older age
patients have worse biological, psychological, and HRQOL
outcomes than transition-age patients. In some instances,
the oldest patients are not the worst with regard to these
outcomes. In contrast, while transition-aged SCD patients
do not have worse biology than older patients, they do have
more utilization for the amount of pain and biological abnormalities seen, compared to older adults. This sheds some
light and adds some validity to current interventions focused
on transition-aged patients. But further study is required to
determine whether analogous, age-appropriate health care or
other interventions could somehow improve the quantity and
quality of life for older, posttransition patients with SCD.
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